Olema Pharmaceuticals, Inc.

This phase 3 study tests whether a new drug called palazestrant, combined with ribociclib, works better than the standard treatment (letrozole plus ribociclib) for people with a common type of advanced breast cancer (ER+/HER2-). About 1,000 adults who have not had prior treatment…

This study tests a new drug, OP-1250, against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can delay cancer growth better than standard care. About 510 adults whose…

This early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow cancer growth. About 180 adults will…

This early-phase study is testing a new drug called OP-1250 (palazestrant) combined with other targeted therapies for people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find the safest dose and understand side effects. About 190 adu…